Business Context and Reporting Period
This Form 8-K Current Report was filed by Prothena Corporation plc on July 22, 2013. The report discloses corporate governance changes, specifically the appointment of a new director and the reorganization of board committees.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Stock Option Grant: 50,000 ordinary shares with an exercise price of $16.42 per share.
- Annual Retainer: $62,000 aggregate (comprising $39,000 base director fee, $10,000 Ireland travel allowance, $10,000 Compensation Committee chair fee, and $3,000 Nominating Committee member fee).
Material Changes
The primary material change reported is the appointment of Dr. Dennis J. Selkoe, M.D., to the Board of Directors on July 22, 2013. Additionally, the Board approved new committee compositions effective July 23, 2013:
- Compensation Committee: Dr. Selkoe appointed as Chair; members include Lars G. Ekman and Richard T. Collier.
- Nominating Committee: Dr. Selkoe appointed as member; Richard T. Collier serves as Chair.
- Audit Committee: Christopher S. Henney serves as Chair; members include Lars G. Ekman and Richard T. Collier.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, risk factors, or discussion of contingencies. The document is strictly limited to the disclosure of the director appointment and associated compensatory arrangements.
Investor Verification Checklist
- Verify the vesting schedule of the 50,000 stock options granted to Dr. Selkoe (vests in full on the first anniversary).
- Confirm the pro-rated payment structure for Dr. Selkoe's 2013 retainer.
- Review the full text of the press release filed as Exhibit 99.1 for additional context on the appointment.